Literature DB >> 2878131

Haemodynamic effects of atrial peptide infusion in heart failure.

I G Crozier, M G Nicholls, H Ikram, E A Espiner, H J Gomez, N J Warner.   

Abstract

The effect of a synthetic analogue of atrial natriuretic peptide (Ileu-ANP) on haemodynamic, hormonal, and electrolyte excretion indices was studied in 7 patients with chronic congestive heart failure. Patients received in random order placebo or Ileu-ANP infusions (5 micrograms/min) for 4 h on 2 separate occasions, at least 1 week apart. Compared with placebo, Ileu-ANP caused significant reductions in mean systemic arterial pressure, mean pulmonary artery pressure, pulmonary diastolic pressure, and right atrial pressure. These changes were sustained for at least 2 h after infusion. Cardiac output increased from 6.2 to 7.4 l/min at 60 min, then returned to pre-infusion levels. Despite considerable falls in systemic pressure there was no significant increase in heart rate or plasma noradrenaline. With Ileu-ANP infusion, plasma renin activity, angiotensin, arginine vasopressin, aldosterone, and cortisol values were not significantly different from placebo values. Plasma cortisol and aldosterone increased after stopping Ileu-ANP. Neither urine volume nor sodium excretion rate was significantly increased by Ileu-ANP.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2878131     DOI: 10.1016/s0140-6736(86)92675-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  26 in total

Review 1.  Heart failure in 10 years time: focus on pharmacological treatment.

Authors:  J J V McMurray
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

2.  Atrial natriuretic peptide and water and electrolyte transport in the human jejunum.

Authors:  J Brunner; R Lübcke; G O Barbezat; T G Yandle; E A Espiner
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

Review 3.  Outpatient management of congestive heart failure.

Authors:  E K Massin
Journal:  Tex Heart Inst J       Date:  1998

4.  Systemic and regional vascular effects of atrial natriuretic peptide in a rat model of chronic heart failure.

Authors:  H Drexler; M Finkh; S Höing; M Toth; H Just; R E Lang
Journal:  Basic Res Cardiol       Date:  1987 Nov-Dec       Impact factor: 17.165

5.  Synthesis of atrial natriuretic polypeptide in human failing hearts. Evidence for altered processing of atrial natriuretic polypeptide precursor and augmented synthesis of beta-human ANP.

Authors:  A Sugawara; K Nakao; N Morii; T Yamada; H Itoh; S Shiono; Y Saito; M Mukoyama; H Arai; K Nishimura
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

Review 6.  Aldosterone receptor blockade in the management of heart failure.

Authors:  Emiliano A Palmieri; Bernadette Biondi; Serafino Fazio
Journal:  Heart Fail Rev       Date:  2002-04       Impact factor: 4.214

Review 7.  Harnessing the therapeutic potential of atrial natriuretic peptide.

Authors:  A G Jardine; D B Northridge; J M Connell
Journal:  Klin Wochenschr       Date:  1989-09-01

Review 8.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

9.  Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure.

Authors:  K B Margulies; M A Perrella; L J McKinley; J C Burnett
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

Review 10.  Molecular forms of natriuretic peptides in heart failure and their implications.

Authors:  Ye Olivia Xu-Cai; Qingyu Wu
Journal:  Heart       Date:  2009-05-17       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.